An executive at Cytokinetics sold 3,500 shares worth about $224,035 as the company's heart disease drug Myqorzo expands in the U.S. and gains approvals in Canada, Germany, and the U.K. Myqorzo has strong prescription growth, accounting for over 40% of new-to-brand prescriptions in its market by mid-2026. Cytokinetics plans further approvals later this year while also issuing shares as employee compensation. The company currently shows a net loss with a high price-to-sales ratio, highlighting investor expectations despite ongoing losses.
Cytokinetics shares are trading at USD 64.68, up 1.14% as of Oct 21, 2026 20:51 WIB on Pluang. The stock shows a market cap of $8.89 billion and a 52-week range between $54.76 and $87.26. This trading context highlights investor interest as the company expands Myqorzo's market presence and navigates its financial challenges.
Cytokinetics, a cardiovascular biopharmaceutical company, granted stock options for 60,465 shares and 40,084 restricted stock units (RSUs) to 29 new employees hired in September and October 2026. The RSUs vest over three years, while the stock option...
Health Canada has approved MYQORZO (aficamten) for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) classified as NYHA class II-III. MYQORZO is an oral drug that reduces heart muscle contractility and obstruction, impro...
